Latest revenue
$24.06B
as of 2026-03-29
Latest net income
$5.24B
as of 2026-03-29
Net margin
21.8%
as of 2026-03-29
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $564.11B
- Enterprise value
- $597.41B
- P/E (trailing)
- 21.0×
- Forward P/E
- —
- P/B
- 6.95×
- Dividend yield
- 2.2%
- 52-wk high
- $251.71
- 52-wk low
- $149.04
- Beta
- —
- Shares out
- 2.41B
5-year trend
What this company does
Johnson & Johnson develops and sells prescription pharmaceuticals and medical devices, spanning oncology, immunology, neuroscience, surgery, and orthopedics. Product sales to hospitals, providers, and distributors generate essentially all revenue, with the drug business driving the bulk of $63.8 billion in nine-month sales. The company just completed its separation of consumer-health unit Kenvue, booking a $21 billion gain and refocusing entirely on higher-margin pharmaceuticals and medtech.
Generated from JNJ's filing dated 2026-02-11
Key risks
- Talc litigation overhang: Other (income)/expense jumped to $7.1B for nine months vs $15M prior year, reflecting massive contingency charges.
- Kenvue separation removed Consumer Health: J&J shed $30B in disc-ops assets, leaving revenue concentrated in Pharma/MedTech and reducing diversification.
- Margin pressure: Continuing-ops earnings fell to $9.2B from $13.1B YoY (nine months), with operating margin halved by litigation/IPR&D charges.
Generated from JNJ's filing dated 2026-02-11
Profitability
Gross margin
67.9%
1.7%Net margin
28.5%
79.7%Return on assets
13.5%
72.3%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-29 | $24.06B | +9.9% | $5.24B | -52.4% | 21.8% |
Q4 2025 2025-12-28 | $24.56B | +9.1% | $5.12B | +49.1% | 20.8% |
Q3 2025 2025-09-28 | $23.99B | +6.8% | $5.15B | +91.2% | 21.5% |
Q2 2025 2025-06-29 | $23.74B | +5.8% | $5.54B | +18.2% | 23.3% |
Q1 2025 2025-03-30 | $21.89B | +2.4% | $11.00B | +237.9% | 50.2% |
Q4 2024 2024-12-29 | $22.52B | — | $3.43B | — | 15.2% |
Q3 2024 2024-09-29 | $22.47B | +5.2% | $2.69B | -89.6% | 12.0% |
Q2 2024 2024-06-30 | $22.45B | +4.3% | $4.69B | -7.7% | 20.9% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on JNJ — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$257.7K
Insider selling
$123.4M
Net activity
−$123.1M
Distinct insiders
9
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns JNJ
Institutional value
$103.62B
Total shares held
433.6M
Distinct holders
753
As of
2026-03-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 156.6M | $38.28B | — | New |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 63.5M | $15.53B | — | New |
| 3 | Legal & General Group Plc | 19.3M | $4.73B | — | New |
| 4 | WELLS FARGO & COMPANY/MN | 16.9M | $4.14B | — | New |
| 5 | DIMENSIONAL FUND ADVISORS LP | 15.8M | $3.87B | — | New |
| 6 | Invesco Ltd. | 15.0M | $3.68B | — | New |
| 7 | VANGUARD FIDUCIARY TRUST CO | 13.6M | $3.32B | — | New |
| 8 | GQG Partners LLC | 7.3M | $1.79B | — | New |
| 9 | Allianz Asset Management GmbH | 5.7M | $1.39B | — | New |
| 10 | Mitsubishi UFJ Asset Management Co., Ltd. | 5.7M | $1.38B | — | New |
| 11 | Vanguard Global Advisers, LLC | 5.3M | $1.30B | — | New |
| 12 | National Pension Service | 5.2M | $1.26B | — | New |
| 13 | TD ASSET MANAGEMENT INC | 4.6M | $1.12B | — | New |
| 14 | STIFEL FINANCIAL CORP | 4.5M | $1.10B | — | New |
| 15 | PNC Financial Services Group, Inc. | 4.5M | $1.09B | — | New |
| 16 | VANGUARD ASSET MANAGEMENT, Ltd | 4.4M | $1.07B | — | New |
| 17 | RHUMBLINE ADVISERS | 3.8M | $936.0M | — | New |
| 18 | Voya Investment Management LLC | 3.7M | $898.7M | — | New |
| 19 | CITIGROUP INC | 2.8M | $692.4M | — | New |
| 20 | BAHL & GAYNOR INC | 2.7M | $665.2M | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
- 1
With Stelara biosimilar erosion imminent, what specific 2025 revenue headwind are you modeling, and which assets bridge the gap?
- 2
Other (income)/expense jumped to $7.1B over nine months—quantify how much relates to talc litigation reserves versus other charges.
- 3
Post-Kenvue, equity fell to $71B and you've spent $4.8B on buybacks; what's the M&A firepower ceiling before losing AAA rating?
Refreshed when JNJ files a new report · last from 2026-02-11